• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.

作者信息

Rankin Brian D, Sood Siddhartha, Park Ye-Jean, Rimke Alexander, Abduelmula Abrahim, Georgakopoulos Jorge R, Maliyar Khalad, Leung Fernejoy, Stark Lauren A, Devani Alim R, Yeung Jensen, Prajapati Vimal H

机构信息

Department of Medicine, Division of Dermatology, University of Calgary, Calgary, Canada.

Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.

出版信息

Dermatitis. 2025 Jul-Aug;36(4):e407-e409. doi: 10.1089/derm.2024.0208. Epub 2024 Oct 24.

DOI:10.1089/derm.2024.0208
PMID:39446652
Abstract
摘要

相似文献

1
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.乌帕替尼治疗青少年和成人特应性皮炎的有效性和安全性：来自一项真实世界多中心回顾性研究的长期（第52周）数据分析
Dermatitis. 2025 Jul-Aug;36(4):e407-e409. doi: 10.1089/derm.2024.0208. Epub 2024 Oct 24.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
4
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.度普利尤单抗、曲罗芦单抗和乌帕替尼在特应性皮炎患者中的真实世界有效性和安全性：一项为期52周的国际多中心回顾性队列研究。
Dermatol Ther (Heidelb). 2025 Aug;15(8):2295-2305. doi: 10.1007/s13555-025-01453-8. Epub 2025 Jun 3.
5
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
6
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.乌帕替尼对比度普利尤单抗治疗成人中重度特应性皮炎的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023.
7
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
8
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).JAK抑制剂在60岁以上中重度特应性皮炎患者中的疗效和安全性：一项为期52周的多中心、真实世界研究——意大利特应性皮炎研究（IL AD）
Arch Dermatol Res. 2025 May 23;317(1):777. doi: 10.1007/s00403-025-04278-9.
9
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
10
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.

引用本文的文献

1
Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis.JAK抑制剂治疗特应性皮炎的真实世界有效性和安全性：一项系统评价和荟萃分析。
Clin Exp Allergy. 2025 Sep;55(9):755-772. doi: 10.1111/cea.70125. Epub 2025 Aug 2.
2
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study.乌帕替尼治疗特应性皮炎患者成功达成严苛治疗目标：一项为期96周的单中心真实世界研究
Dermatol Ther (Heidelb). 2025 Jan;15(1):227-235. doi: 10.1007/s13555-024-01334-6. Epub 2025 Jan 15.